Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice

• Published in: International journal of molecular sciences Vol. 24; no. 9; p. 8099
• Main Authors: Cesaro, Arturo, Acerbo, Vincenzo, Vetrano, Erica, Signore, Giovanni, Scherillo, Gianmaria, Rotolo, Francesco Paolo, De Michele, Gianantonio, Scialla, Francesco, Raucci, Giuseppe, Panico, Domenico, Gragnano, Felice, Moscarella, Elisabetta, Galiero, Raffaele, Caturano, Alfredo, Ruggiero, Roberto, Sasso, Ferdinando Carlo, Calabrò, Paolo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30.04.2023; MDPI
• Subjects: Adipose tissue; adverse event; Adverse events; Anthropometry; Antidiabetics; Blood; Blood pressure; Body mass index; Body size; Body weight; CAD; Cardiovascular disease; Cardiovascular diseases; Clinical medicine; Clinical trials; Complications and side effects; Coronary artery disease; Coronary Artery Disease - complications; Coronary Artery Disease - drug therapy; Coronary heart disease; Coronary vessels; Dextrose; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - chemically induced; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes therapy; Diabetic ketoacidosis; Diabetics; Drug therapy; Drugs; Gangrene; Glucagon; Glucose; Glucose - therapeutic use; Glycated Hemoglobin; Glycosylated hemoglobin; GUTI; Health services; Heart attacks; Heart diseases; Humans; Hypoglycemic agents; Hypoglycemic Agents - adverse effects; Inhibitors; Insulin; Intolerance; Ketoacidosis; Medical examination; Medical research; Medicine, Experimental; Metabolism; Molecular modelling; Patients; Peptides; SGLT2 inhibitors (SGLT2i); Sodium; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Type 2 diabetes; type 2 diabetes mellitus (T2DM); Vein & artery diseases; adverse event; GUTI; SGLT2 inhibitors (SGLT2i); type 2 diabetes mellitus (T2DM); CAD

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were initially developed for the treatment of diabetes due to their antihyperglycemic activity. However, in the light of the most recent clinical studies, they are revolutionizing the approach to cardiovascular disease in patients with and without d...